Gilead Analyst: FDA's Remdesivir Label A Best Case Scenario For Biopharma
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Gilead Analyst: FDA's Remdesivir Label A Best Case Scenario For Biopharma
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
Steven Seedhouse Recent News
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
Mirum Pharma's Lead Asset Has $450M Sales Opportunity, Raymond James Says In Bullish Initiation
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock
Citi Believes Reata Has 'Considerable Room' To Operate In $5 Billion PAH Market